SLAB Stock Analysis: Silicon Laboratories | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 7.374m USD | 12M Return: 64.5% | US8269191024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.5M
Qual. Beats: -1
Rev. Trend: 21.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Silicon Laboratories Inc. (SLAB) is a fabless semiconductor company headquartered in Austin, Texas, founded in 1996. The company designs and sells mixed-signal, analog-intensive semiconductor products targeting Internet of Things (IoT) applications across industrial, commercial, smart home, and connected health markets.
Its product portfolio serves a broad range of end uses, including industrial automation, smart metering, renewable energy, EV charging equipment, asset tracking, smart lighting, access controls, home automation devices (locks, cameras, HVAC, sensors), and connected health applications like patient monitoring and diabetes management. Silicon Labs distributes its products through a direct sales force as well as independent sales representatives and distributors, with operations spanning the U.S., Taiwan, China, and other international markets.
As a fabless semiconductor company, Silicon Labs outsources wafer fabrication to third-party foundries, focusing internal resources on chip design, firmware, and software development-a model that reduces capital expenditure requirements and is widely used across the semiconductor industry, particularly for IoT-focused chipmakers serving fragmented end markets.
- IoT chip demand recovery boosts industrial segment revenue
- China revenue concentration raises export control risk
- Wireless microcontroller pricing pressure compresses gross margins
| Net Income: -39.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -6.58 > 1.0 |
| NWC/Revenue: 63.92% < 20% (prev 70.69%; Δ -6.77% < -1%) |
| CFO/TA 0.03 > 3% & CFO 33.1m > Net Income -39.1m |
| Current Ratio: 5.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.2m) vs 12m ago 1.60% < -2% |
| Gross Margin: 59.90% > 18% (prev 54.95%; Δ 4.95% > 0.5%) |
| Asset Turnover: 69.19% > 50% (prev 57.59%; Δ 11.60% > 0%) |
| Interest Coverage Ratio: -34.10 > 6 (EBIT TTM -31.5m / Interest Expense TTM 923k) |
| A: 0.44 (Total Current Assets 671.2m - Total Current Liabilities 124.1m) / Total Assets 1.25b |
| B: 0.73 (Retained Earnings 910.3m / Total Assets 1.25b) |
| C: -0.03 (EBIT TTM -31.5m / Avg Total Assets 1.24b) |
| D: 6.92 (Book Value of Equity 1.09b / Total Liabilities 158.3m) |
| Altman-Z'' = 12.33 = AAA |
| DSRI: 1.16 (Receivables 79.8m/56.5m, Revenue 855.9m/703.2m) |
| GMI: 0.92 (GM 54.95% / 59.90%) |
| AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.22 (Revenue 855.9m / 703.2m) |
| TATA: -0.06 (NI -39.1m - CFO 33.1m) / TA 1.25b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of October 27, 2026, the stock is trading at USD 221.27 with a total of 262,259 shares traded. Over the past week, the price has changed by +0.12%, over one month by +0.01%, over three months by +2.08% and over the past year by +64.54%.
Current recommended Stop Loss: 219.00 (which is 1% or 2.5 ATR below the current price).
Silicon Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold SLAB.
- StrongBuy: 0
- Buy: 0
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 222.9 | 0.7% |
P/E Forward = 51.0204
P/S = 8.6156
P/B = 6.7422
P/EG = 3.1179
Revenue TTM = 855.9m USD
EBIT TTM = -31.5m USD
EBITDA TTM = 1.89m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 24.0m USD (Leases only: 24.0m)
Net Debt = -373.3m USD (calculated: Debt 24.0m - CCE 397.2m)
Enterprise Value = 7.00b USD (7.37b + Debt 24.0m - CCE 397.2m)
Interest Coverage Ratio = -34.10 (Ebit TTM -31.5m / Interest Expense TTM 923k)
EV/FCF = -1000.0x (Enterprise Value 7.00b / FCF TTM -5.43m)
FCF Yield = -0.08% (FCF TTM -5.43m / Enterprise Value 7.00b)
FCF Margin = -0.63% (FCF TTM -5.43m / Revenue TTM 855.9m)
Net Margin = -4.57% (Net Income TTM -39.1m / Revenue TTM 855.9m)
Gross Margin = 59.90% ((Revenue TTM 855.9m - Cost of Revenue TTM 343.2m) / Revenue TTM)
Gross Margin QoQ = 61.65% (prev 56.65%)
Tobins Q-Ratio = 5.59 (Enterprise Value 7.00b / Total Assets 1.25b)
Interest Expense / Debt = 3.85% (Interest Expense 923k / Debt 24.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -24.9m (EBIT -31.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.41 (Total Current Assets 671.2m / Total Current Liabilities 124.1m)
Debt / Equity = 0.02 (Debt 24.0m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = -197.6 (out of range, set to none) (Net Debt -373.3m / EBITDA 1.89m)
Debt / FCF = 68.72 (negative FCF - burning cash) (Net Debt -373.3m / FCF TTM -5.43m)
Total Stockholder Equity = 1.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.16% (Net Income -39.1m / Total Assets 1.25b)
RoE = -3.59% (Net Income TTM -39.1m / Total Stockholder Equity 1.09b)
RoCE = -2.79% (EBIT -31.5m / Capital Employed (Total Assets 1.25b - Current Liab 124.1m))
RoIC = -2.29% (negative operating profit) (NOPAT -24.9m / Invested Capital 1.09b)
WACC = 10.25% (E(7.37b)/V(7.40b) * Re(10.27%) + D(24.0m)/V(7.40b) * Rd(3.85%) * (1-Tc(0.21)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.17 | Cagr: 1.79%
[DCF] Fair Price = unknown (Cash Flow -5.43m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 21.92 | Revenue CAGR: 4.78% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.85 | Chg30d=+0.00% | Revisions=+12% | Analysts=7
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=-1.55% | Revisions=+12% | GrowthEPS=+212.7% | GrowthRev=+18.1%
EPS next Year (2027-12-31): EPS=4.36 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+51.6% | GrowthRev=+16.5%
[Analyst] Revisions Ratio: +12% (up=8, down=6)